India's COVID vaccinations hit 2 billion, new cases at four-month high
Reuters
Published Jul 17, 2022 08:10AM ET
NEW DELHI (Reuters) - The Indian government's COVID-19 vaccinations hit 2 billion on Sunday, with booster doses underway for all adults, as daily infections hit four-month high, official data showed.
Prime Minister Narendra Modi extolled the vaccination milestone, celebrating the world's largest and longest-running inoculation campaign, which began last year.
"India creates history again!" Modi said in a tweet. The prime minister has faced allegations from the opposition of mishandling the pandemic that experts claim killed millions. The government rejects the claims.
Health ministry data shows the COVID death toll at 525,709, with 49 deaths recorded overnight.
New cases rose 20,528 over the past 24 hours, the highest since Feb. 20, according to data compiled by Reuters.
The country of 1.35 billion people has lifted most COVID-related restrictions, and international travel has recovered robustly.
Some 80% of the inoculations have been the AstraZeneca (NASDAQ:AZN) vaccine made domestically, called Covishield. Others include domestically developed Covaxin and Corbevax, and Russia's Sputnik V.
The federal government has been accelerating its booster campaign to avert the spread of infections, edging higher in the eastern states of Assam, West Bengal and Karnataka in the south.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.